The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Read about the characteristic symptoms of fragile X syndrome, which range from developmental and behavioral problems to physical features.| Fragile X News Today
Fragile X syndrome is caused by low to no levels of the FMRP protein, important for brain development, due to mutations in the FMR1 gene.| Fragile X News Today
Category archive page for News.| Fragile X News Today
Marisa Wexler is a senior science writer for Fragile X News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of fragile X topics.| Fragile X News Today
Learn about fragile X syndrome, the most common cause of inherited intellectual disability and autism spectrum disorders.| Fragile X News Today
